ARMET AS A MARKER FOR CANCER

摘要

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the arginine-rich metastasized in early tumors protein (= ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g. of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are e.g. breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in said sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.